Citation profile for Philippe GORRY

Philippe GORRY : Citation Profile

Université de Bordeaux

H index

i10 index

Citations

RESEARCH PRODUCTION:

Articles

Papers

Chapters

RESEARCH ACTIVITY:

   12 years (2010 - 2022). See details.
   Cites by year: 2
   Journals where Philippe GORRY has often published
   Relations with other researchers
   Recent citing documents: 2.    Total self citations: 3 (10.34 %)

MORE DETAILS IN:

EconPapers Author's homepage

ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pgo436
   Updated: 2024-11-06    RAS profile: 2022-12-01
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers

Works with:

Piveteau, Alain (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Philippe GORRY.

Is cited by:

Bornmann, Lutz (3)

Harhoff, Dietmar (1)

Hanks, Andrew (1)

Hall, Bronwyn (1)

Cites to:

Leydesdorff, Loet (2)

Bornmann, Lutz (2)

Morrill, Melinda (1)

van Dalen, Hendrik (1)

Bokhari, Farasat (1)

evans, william (1)

Vieira, Pedro (1)

Teixeira, Aurora (1)

Main data

Where Philippe GORRY has published?

Journals with more than one article published	# docs
Scientometrics	2
Revue de la R�gulation - Capitalisme, institutions, pouvoirs	2

Working Papers Series with more than one paper published	# docs
Post-Print / HAL	72

Recent works citing Philippe GORRY (2024 and 2023)

Year	Title of citing document
2023	Altmetrics-based sleeping beauties: necessity or just a supplement?. (2023). Li, Hao ; Hou, Jianhua ; Zhang, Yang. In: Scientometrics. RePEc:spr:scient:v:128:y:2023:i:10:d:10.1007_s11192-023-04798-z. Full description at Econpapers \|\| Download paper

Works by Philippe GORRY:

Year	Title	Type	Cited
2012	Construction politique des marchés et politiques des prix. Le cas de lindustrie pharmaceutique In: Post-Print. [Citation analysis]	paper	0
2011	Regulating the drugs market in the EU: the contradiction between safety, innovation and access to care In: Post-Print. [Citation analysis]	paper	0
2011	Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS) In: Post-Print. [Citation analysis]	paper	0
2013	CH2 Une demande structurée par les prescripteur & CH3 Un système dominé par les firmes multinationales pharmaceutiques In: Post-Print. [Citation analysis]	paper	0
2010	The political construction of orphan drugs market: between innovation & access to care In: Post-Print. [Citation analysis]	paper	0
2010	Impact of market exclusivity versus IP protection in fostering innovation for rare diseases In: Post-Print. [Citation analysis]	paper	0
2012	Schéma régional de lenseignement supérieur, de la recherche & de linnovation In: Post-Print. [Citation analysis]	paper	0
2018	Exploring the historical roots of mesenchymal stem cell research using reference publication year spectroscopy In: Post-Print. [Citation analysis]	paper	0
2016	Health innovation for rare diseases In: Post-Print. [Citation analysis]	paper	1
2014	Building an orphan drug market database to enpower decision making by patient organizations & pharma-biotech companies In: Post-Print. [Citation analysis]	paper	0
2014	Les enjeux de la reconnaissance de la radiologie interventionnelle : un travail de recherche interdisciplinaire (sociologie, économie, droit) In: Post-Print. [Citation analysis]	paper	0
2015	Construction of mental health categories In: Post-Print. [Full Text][Citation analysis]	paper	1
2015	Mapping scientific dynamics in « Regenerative Medicine » research, Tissue Engineering Part A, 21, S1 In: Post-Print. [Citation analysis]	paper	0
2014	Institutionnalisation des politiques publiques de santé & diffusion de l’innovation médicale In: Post-Print. [Citation analysis]	paper	0
2014	Approche quantitative de la diffusion d’un innovation: exemple de la radiologie interventionnelle In: Post-Print. [Citation analysis]	paper	0
2014	Institutionalizarion of public policies & diffusion of innovation: the case of interventional radiology In: Post-Print. [Citation analysis]	paper	0
2014	Diagnostic prénatal non invasif sur sang maternel & Propriété Intellectuelle: entre éthique de la santé et efficience du marché In: Post-Print. [Citation analysis]	paper	0
2015	Intellectual Property Rights and Traditional Knowledge: to which extend biodiversity is preempted at the global level In: Post-Print. [Citation analysis]	paper	0
2015	Charles Dotter & the birth of Interventional Radiology: A sleeping beauty with a restless sleep In: Post-Print. [Citation analysis]	paper	0
2015	L’histoire de la radiologie interventionnelle: développement et diffusion d’une innovation médicale In: Post-Print. [Citation analysis]	paper	0
2016	Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech Companies In: Post-Print. [Citation analysis]	paper	0
2015	Orphan Drug Designations as Valuable intangible assets for Ipo Investors in Pharma-biotech companies.(2015) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0	paper
2018	Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies.(2018) In: NBER Chapters. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 0	chapter
2017	Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies..(2017) In: NBER Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 0	paper
2016	Serendipity and university technology transfer: a case study. In: Post-Print. [Citation analysis]	paper	0
2016	Empirical economic analysis of orphan drug legislation impact on innovation In: Post-Print. [Citation analysis]	paper	0
2016	Empirical Economic Analysis of Orphan Drug Legislation Impact on Innovation.(2016) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0	paper
2016	Pharma Competitive Intelligence using open source data and visualization tool: towards metrics for drug R&D milestones In: Post-Print. [Citation analysis]	paper	0
2016	Biodiversity Sustainability of Phytomedicine Research: a 3-dimensions analysis around the North-South divide In: Post-Print. [Citation analysis]	paper	0
2016	Empirical Economic Analysis of Orphan Drug Innovation In: Post-Print. [Citation analysis]	paper	0
2017	Empirical Economic Analysis of Orphan Drug Innovation.(2017) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0	paper
2016	Empirical Economic Analysis of Orphan Drug Innovation.(2016) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0	paper
2017	Orphan Drugs: Why the US legislation approves more than the EU? In: Post-Print. [Citation analysis]	paper	0
2017	Social Recognition of a Medical Innovation: the case of Interventional Radiology in Oncology In: Post-Print. [Citation analysis]	paper	0
2017	Neologisms and affiliation name: a bibliometric perspective on the institutionalization of interventional radiology In: Post-Print. [Citation analysis]	paper	0
2017	Evolution des prescriptions de médicaments orphelins en cancérologie : en France, et à l’échelle d’un établissement hospitalier In: Post-Print. [Citation analysis]	paper	0
2016	Evolution des prescriptions de médicaments orphelins en cancérologie: en France et à l’échelle d’un établissement hospitalier.(2016) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0	paper
2018	Orphan Drug Market Exclusivity Extension versus Patent Monopoly In: Post-Print. [Citation analysis]	paper	0
2018	Does Orphan Drug market exclusivity incentive sustains drug development for rare diseases ? In: Post-Print. [Citation analysis]	paper	0
2018	Naming institution after neologism as marker of the institutionalization of new discipline In: Post-Print. [Citation analysis]	paper	0
2018	Delayed Recognition in Science: Different Causes of Sleeping and Awakening of Discoveries In: Post-Print. [Citation analysis]	paper	0
2014	Ultrasons focalisés de haute intensité : analyse des dynamiques d’innovations In: Post-Print. [Citation analysis]	paper	0
2015	Medical literature imprinting by pharma ghost writing: a scientometric evaluation In: Post-Print. [Citation analysis]	paper	0
2015	Mapping scientific dynamics in « Regenerative Medicine » research In: Post-Print. [Citation analysis]	paper	0
2015	Diffusion of Interventional Radiology and Health Technology Assessment: the case of radiofrequency treatment in oncology In: Post-Print. [Citation analysis]	paper	0
2016	Towards a Patent landscaping of Regenerative Medicine In: Post-Print. [Citation analysis]	paper	1
2017	Angiogenesis inhibitors drug pipeline landscape In: Post-Print. [Citation analysis]	paper	0
2017	Orphan Drug legislation: evaluation of the impact of market exclusivity extension In: Post-Print. [Citation analysis]	paper	0
2017	Science and Technology Indicators of Microalgae-Based Biofuel Research In: Post-Print. [Citation analysis]	paper	0
2017	The Dissemination of the Concept of “Interventional Radiology” in Medical and Scientific Literature In: Post-Print. [Citation analysis]	paper	0
2017	The Dissemination of the Concept of “Interventional Radiology” in Medical and Scientific Literature.(2017) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0	paper
2018	Impact of Health Technology Assessment on Innovation Diffusion: the case of techniques in Interventional Radiology. In: Post-Print. [Citation analysis]	paper	0
2019	Market Valuation of FDA Orphan Drug Regulatory Events In: Post-Print. [Citation analysis]	paper	2
2019	Global overview of patenting landscape in unmanned aerial vehicles. In: Post-Print. [Citation analysis]	paper	0
2019	Drug Safety scientometrics overview highlights public health issues. In: Post-Print. [Citation analysis]	paper	0
2013	HTA National Public Policy and Their Socio-Economic Environment: A European Perspective In: Post-Print. [Citation analysis]	paper	0
2019	R&D incentives and innovation spillovers: evidence from the European orphan drug regulation. In: Post-Print. [Citation analysis]	paper	0
2013	Analyse sectorielle, technologique et économique, du marché des médicaments orphelins. In: Post-Print. [Citation analysis]	paper	0
2013	A patent landscaping of medicinal plants extracts In: Post-Print. [Citation analysis]	paper	0
2013	The scientific-knowledge based institutionalization of Health Technology Assessment: a bibliometric and network analysis In: Post-Print. [Citation analysis]	paper	0
2016	Website: orphandrugseconomics.org In: Post-Print. [Citation analysis]	paper	0
2016	Economie de la santé : les médicaments orphelins In: Post-Print. [Citation analysis]	paper	0
2020	Pourquoi les prix des traitements contre les maladies rares deviennent fous ? In: Post-Print. [Citation analysis]	paper	0
2019	Atelier Accès à linnovation In: Post-Print. [Citation analysis]	paper	0
2015	Does scientific knowledge play a role in public policies? A contribution of scientometrics to political science: the case of HTA In: Post-Print. [Citation analysis]	paper	0
2015	Naissances de la radiologie interventionnelle. Le rôle de Charles T. Dotter In: Post-Print. [Citation analysis]	paper	0
2020	Impact de la législation européenne des médicaments orphelins sur le marché global du médicament In: Post-Print. [Citation analysis]	paper	0
2020	Assessment of generic competition for Orphan Drugs marketed in the US (1993-2019) In: Post-Print. [Citation analysis]	paper	0
2020	Le statut de médicament orphelin est un signal positif pour les investisseurs lors de lintroduction en bourse des sociétés de biotechnologie In: Post-Print. [Citation analysis]	paper	0
2020	Médicaments orphelins et maladies rares sur Twitter In: Post-Print. [Citation analysis]	paper	0
2021	Beyond health security dependencies. Rethinking public health and industrial policies construction In: Post-Print. [Citation analysis]	paper	0
2022	Drug shortages, APIs supply & Pharma Global Value Chain In: Post-Print. [Citation analysis]	paper	0
2013	Health Technology Assessment Agencies and their economic environment: a European perspective. In: Post-Print. [Citation analysis]	paper	0
2014	The EUs Government of Pharmaceuticals: Incompleteness Embraced In: Post-Print. [Citation analysis]	paper	0
2017	Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021. In: Working Papers. [Citation analysis]	paper	0
2015	La construction des catÃ©gories diagnostiques de maladie mentale In: Revue de la Régulation - Capitalisme, institutions, pouvoirs. [Full Text][Citation analysis]	article	0
2021	Sécurité sanitaire sous dépendance. Une construction politique à repenser In: Revue de la Régulation - Capitalisme, institutions, pouvoirs. [Full Text][Citation analysis]	article	0
2016	“Sleeping beauty” and her restless sleep: Charles Dotter and the birth of interventional radiology In: Scientometrics. [Full Text][Citation analysis]	article	12
2018	Delayed recognition of Judah Folkman’s hypothesis on tumor angiogenesis: when a Prince awakens a Sleeping Beauty by self-citation In: Scientometrics. [Full Text][Citation analysis]	article	9